Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
24
THW Quote, Financials, Valuation and Earnings
Last price:
$10.23
Seasonality move
:
-1.9%
Day range:
$10.16 - $10.27
52-week range:
$9.80 - $13.48
Dividend yield:
9.12%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
206.7K
Avg. volume:
143.7K
1-year change:
-22.19%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
THW
Tekla World Healthcare Fund
|
-- | -- | -- | -- | -- |
|
GRX
Gabelli Healthcare & WellnessRx Trust
|
-- | -- | -- | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | -- | -- | -- | -- |
|
THQ
abrdn Healthcare Opportunities Fund
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
THW
Tekla World Healthcare Fund
|
$10.24 | -- | -- | -- | $0.12 | 9.12% | -- |
|
GRX
Gabelli Healthcare & WellnessRx Trust
|
$9.42 | -- | -- | -- | $0.17 | 6.58% | -- |
|
HQL
abrdn Life Sciences Investors
|
$13.16 | -- | -- | -- | $0.43 | 6.84% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$65.62 | -- | -- | -- | $0.13 | 0.25% | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
$39.48 | -- | -- | -- | $0.00 | 0.09% | -- |
|
THQ
abrdn Healthcare Opportunities Fund
|
$17.64 | -- | -- | -- | $0.18 | 7.14% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
THW
Tekla World Healthcare Fund
|
-- | 0.704 | -- | -- |
|
GRX
Gabelli Healthcare & WellnessRx Trust
|
-- | 0.575 | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | 1.039 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.915 | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | 1.111 | -- | -- |
|
THQ
abrdn Healthcare Opportunities Fund
|
-- | 0.682 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
THW
Tekla World Healthcare Fund
|
-- | -- | -- | -- | -- | -- |
|
GRX
Gabelli Healthcare & WellnessRx Trust
|
-- | -- | -- | -- | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | -- | -- | -- | -- | -- |
|
THQ
abrdn Healthcare Opportunities Fund
|
-- | -- | -- | -- | -- | -- |
Tekla World Healthcare Fund vs. Competitors
-
Which has Higher Returns THW or GRX?
Gabelli Healthcare & WellnessRx Trust has a net margin of -- compared to Tekla World Healthcare Fund's net margin of --. Tekla World Healthcare Fund's return on equity of -- beat Gabelli Healthcare & WellnessRx Trust's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THWTekla World Healthcare Fund-- -- -- GRXGabelli Healthcare & WellnessRx Trust-- -- -- -
What do Analysts Say About THW or GRX?
Tekla World Healthcare Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Gabelli Healthcare & WellnessRx Trust has an analysts' consensus of -- which suggests that it could fall by --. Given that Tekla World Healthcare Fund has higher upside potential than Gabelli Healthcare & WellnessRx Trust, analysts believe Tekla World Healthcare Fund is more attractive than Gabelli Healthcare & WellnessRx Trust.
Company Buy Ratings Hold Ratings Sell Ratings THWTekla World Healthcare Fund0 0 0 GRXGabelli Healthcare & WellnessRx Trust0 0 0 -
Is THW or GRX More Risky?
Tekla World Healthcare Fund has a beta of 0.865, which suggesting that the stock is 13.55% less volatile than S&P 500. In comparison Gabelli Healthcare & WellnessRx Trust has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.513%.
-
Which is a Better Dividend Stock THW or GRX?
Tekla World Healthcare Fund has a quarterly dividend of $0.12 per share corresponding to a yield of 9.12%. Gabelli Healthcare & WellnessRx Trust offers a yield of 6.58% to investors and pays a quarterly dividend of $0.17 per share. Tekla World Healthcare Fund pays -- of its earnings as a dividend. Gabelli Healthcare & WellnessRx Trust pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THW or GRX?
Tekla World Healthcare Fund quarterly revenues are --, which are smaller than Gabelli Healthcare & WellnessRx Trust quarterly revenues of --. Tekla World Healthcare Fund's net income of -- is lower than Gabelli Healthcare & WellnessRx Trust's net income of --. Notably, Tekla World Healthcare Fund's price-to-earnings ratio is -- while Gabelli Healthcare & WellnessRx Trust's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tekla World Healthcare Fund is -- versus -- for Gabelli Healthcare & WellnessRx Trust. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THWTekla World Healthcare Fund-- -- -- -- GRXGabelli Healthcare & WellnessRx Trust-- -- -- --
-
Which has Higher Returns THW or HQL?
abrdn Life Sciences Investors has a net margin of -- compared to Tekla World Healthcare Fund's net margin of --. Tekla World Healthcare Fund's return on equity of -- beat abrdn Life Sciences Investors's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THWTekla World Healthcare Fund-- -- -- HQLabrdn Life Sciences Investors-- -- -- -
What do Analysts Say About THW or HQL?
Tekla World Healthcare Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand abrdn Life Sciences Investors has an analysts' consensus of -- which suggests that it could fall by --. Given that Tekla World Healthcare Fund has higher upside potential than abrdn Life Sciences Investors, analysts believe Tekla World Healthcare Fund is more attractive than abrdn Life Sciences Investors.
Company Buy Ratings Hold Ratings Sell Ratings THWTekla World Healthcare Fund0 0 0 HQLabrdn Life Sciences Investors0 0 0 -
Is THW or HQL More Risky?
Tekla World Healthcare Fund has a beta of 0.865, which suggesting that the stock is 13.55% less volatile than S&P 500. In comparison abrdn Life Sciences Investors has a beta of 0.792, suggesting its less volatile than the S&P 500 by 20.833%.
-
Which is a Better Dividend Stock THW or HQL?
Tekla World Healthcare Fund has a quarterly dividend of $0.12 per share corresponding to a yield of 9.12%. abrdn Life Sciences Investors offers a yield of 6.84% to investors and pays a quarterly dividend of $0.43 per share. Tekla World Healthcare Fund pays -- of its earnings as a dividend. abrdn Life Sciences Investors pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THW or HQL?
Tekla World Healthcare Fund quarterly revenues are --, which are smaller than abrdn Life Sciences Investors quarterly revenues of --. Tekla World Healthcare Fund's net income of -- is lower than abrdn Life Sciences Investors's net income of --. Notably, Tekla World Healthcare Fund's price-to-earnings ratio is -- while abrdn Life Sciences Investors's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tekla World Healthcare Fund is -- versus -- for abrdn Life Sciences Investors. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THWTekla World Healthcare Fund-- -- -- -- HQLabrdn Life Sciences Investors-- -- -- --
-
Which has Higher Returns THW or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Tekla World Healthcare Fund's net margin of --. Tekla World Healthcare Fund's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THWTekla World Healthcare Fund-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About THW or PBE?
Tekla World Healthcare Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tekla World Healthcare Fund has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Tekla World Healthcare Fund is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings THWTekla World Healthcare Fund0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is THW or PBE More Risky?
Tekla World Healthcare Fund has a beta of 0.865, which suggesting that the stock is 13.55% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.810, suggesting its less volatile than the S&P 500 by 19.007%.
-
Which is a Better Dividend Stock THW or PBE?
Tekla World Healthcare Fund has a quarterly dividend of $0.12 per share corresponding to a yield of 9.12%. Invesco Biotechnology & Genome ETF offers a yield of 0.25% to investors and pays a quarterly dividend of $0.13 per share. Tekla World Healthcare Fund pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THW or PBE?
Tekla World Healthcare Fund quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Tekla World Healthcare Fund's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Tekla World Healthcare Fund's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tekla World Healthcare Fund is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THWTekla World Healthcare Fund-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns THW or PSCH?
Invesco S&P SmallCap Health Care ETF has a net margin of -- compared to Tekla World Healthcare Fund's net margin of --. Tekla World Healthcare Fund's return on equity of -- beat Invesco S&P SmallCap Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THWTekla World Healthcare Fund-- -- -- PSCHInvesco S&P SmallCap Health Care ETF-- -- -- -
What do Analysts Say About THW or PSCH?
Tekla World Healthcare Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P SmallCap Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tekla World Healthcare Fund has higher upside potential than Invesco S&P SmallCap Health Care ETF, analysts believe Tekla World Healthcare Fund is more attractive than Invesco S&P SmallCap Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings THWTekla World Healthcare Fund0 0 0 PSCHInvesco S&P SmallCap Health Care ETF0 0 0 -
Is THW or PSCH More Risky?
Tekla World Healthcare Fund has a beta of 0.865, which suggesting that the stock is 13.55% less volatile than S&P 500. In comparison Invesco S&P SmallCap Health Care ETF has a beta of 0.958, suggesting its less volatile than the S&P 500 by 4.237%.
-
Which is a Better Dividend Stock THW or PSCH?
Tekla World Healthcare Fund has a quarterly dividend of $0.12 per share corresponding to a yield of 9.12%. Invesco S&P SmallCap Health Care ETF offers a yield of 0.09% to investors and pays a quarterly dividend of $0.00 per share. Tekla World Healthcare Fund pays -- of its earnings as a dividend. Invesco S&P SmallCap Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THW or PSCH?
Tekla World Healthcare Fund quarterly revenues are --, which are smaller than Invesco S&P SmallCap Health Care ETF quarterly revenues of --. Tekla World Healthcare Fund's net income of -- is lower than Invesco S&P SmallCap Health Care ETF's net income of --. Notably, Tekla World Healthcare Fund's price-to-earnings ratio is -- while Invesco S&P SmallCap Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tekla World Healthcare Fund is -- versus -- for Invesco S&P SmallCap Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THWTekla World Healthcare Fund-- -- -- -- PSCHInvesco S&P SmallCap Health Care ETF-- -- -- --
-
Which has Higher Returns THW or THQ?
abrdn Healthcare Opportunities Fund has a net margin of -- compared to Tekla World Healthcare Fund's net margin of --. Tekla World Healthcare Fund's return on equity of -- beat abrdn Healthcare Opportunities Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THWTekla World Healthcare Fund-- -- -- THQabrdn Healthcare Opportunities Fund-- -- -- -
What do Analysts Say About THW or THQ?
Tekla World Healthcare Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand abrdn Healthcare Opportunities Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that Tekla World Healthcare Fund has higher upside potential than abrdn Healthcare Opportunities Fund, analysts believe Tekla World Healthcare Fund is more attractive than abrdn Healthcare Opportunities Fund.
Company Buy Ratings Hold Ratings Sell Ratings THWTekla World Healthcare Fund0 0 0 THQabrdn Healthcare Opportunities Fund0 0 0 -
Is THW or THQ More Risky?
Tekla World Healthcare Fund has a beta of 0.865, which suggesting that the stock is 13.55% less volatile than S&P 500. In comparison abrdn Healthcare Opportunities Fund has a beta of 0.909, suggesting its less volatile than the S&P 500 by 9.122%.
-
Which is a Better Dividend Stock THW or THQ?
Tekla World Healthcare Fund has a quarterly dividend of $0.12 per share corresponding to a yield of 9.12%. abrdn Healthcare Opportunities Fund offers a yield of 7.14% to investors and pays a quarterly dividend of $0.18 per share. Tekla World Healthcare Fund pays -- of its earnings as a dividend. abrdn Healthcare Opportunities Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THW or THQ?
Tekla World Healthcare Fund quarterly revenues are --, which are smaller than abrdn Healthcare Opportunities Fund quarterly revenues of --. Tekla World Healthcare Fund's net income of -- is lower than abrdn Healthcare Opportunities Fund's net income of --. Notably, Tekla World Healthcare Fund's price-to-earnings ratio is -- while abrdn Healthcare Opportunities Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tekla World Healthcare Fund is -- versus -- for abrdn Healthcare Opportunities Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THWTekla World Healthcare Fund-- -- -- -- THQabrdn Healthcare Opportunities Fund-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 13.2% over the past day.
